Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Eli Lilly and Company is conducting a Phase 1 clinical study titled ‘A Study of LY4064912 in Healthy Participants and With Overweight or Obesity.’ The study aims to evaluate the safety, tolerability, and pharmacokinetics of LY4064912, a drug administered either subcutaneously or intravenously, in healthy individuals and those with overweight or obesity. This research is significant as it explores potential treatments for obesity-related conditions.
The intervention being tested is LY4064912, which is administered both subcutaneously and intravenously. The primary goal is to assess how well the drug is tolerated and to identify any side effects in the participants.
The study design is interventional, with a randomized allocation and a sequential intervention model. It employs a double-masking approach, meaning both participants and investigators are unaware of the treatment assignments. The primary purpose of the study is basic science, focusing on understanding the drug’s effects.
The study began on August 26, 2025, and the last update was submitted on September 2, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data.
This update may influence Eli Lilly’s stock performance positively, as successful trials could lead to new treatments for obesity, a growing global health issue. Investors should watch for further developments, as competitors in the pharmaceutical industry are also exploring similar treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.